“We had a highly eventful third quarter which included going public, closing on over $475 million in proceeds across two transactions and continuing to progress our very promising co-lead programs,” said Lawrence Klein, PhD, Chief Executive Officer of Oruka. “We are excited to soon transition to a clinical stage company and show the potential of our programs to raise the bar on what is possible in psoriatic disease.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ORKA:
- Oruka Therapeutics initiated with a Buy at Stifel
- Oruka Therapeutics initiated with a Buy at H.C. Wainwright
- Oruka Therapeutics Adjusts Executive Severance Agreements
- Oruka Therapeutics announces preclinical data for ORKA-001
- Oruka Therapeutics initiated with an Outperform at Leerink
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
